Management of follow-up of neuroendocrine neoplasias

Ulrich Frank Pape, Sebastian Maasberg, Henning Jann, René Pschowski, Sandrine Krüger, Vikas Prasad, Timm Denecke, Bertram Wiedenmann, Andreas Pascher

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Neuroendocrine neoplasias (NEN) comprise heterogeneous epithelial neoplasms with a large variety of clinical presentations, treatment options and outcomes. Since potentially all NEN bear malignant potential it is important for long-term clinical management and improvement of outcome to decide on successful and oncologically and economically meaningful follow-up strategies. Evidence-based outcome data validating specific follow-up strategies are, however, not available to date and thus outcome data, known prognostic factors and clinical experience guide the decisions on follow-up regimens. The review summarizes general recommendations as well as specific considerations based on tumor entities, clinicopathological tumor characteristics and clinical experience. Follow-up shall serve the patient to improve outcome, benefit from more effective therapies and suffer less from unnecessary and/or toxic therapeutic interventions and finally preserve or gain a good quality of life.

Original languageEnglish
Pages (from-to)129-140
Number of pages12
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2016

Keywords

  • follow-up
  • grading
  • neuroendocrine neoplasia
  • outcome
  • primary tumor
  • prognosis
  • quality of life
  • staging

Fingerprint

Dive into the research topics of 'Management of follow-up of neuroendocrine neoplasias'. Together they form a unique fingerprint.

Cite this